XML 40 R5.htm IDEA: XBRL DOCUMENT v3.22.0.1
CONSOLIDATED STATEMENTS REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Redeemable Convertible Preferred Stock
Beginning Balance, Shares at Dec. 31, 2019         75,727,268
Beginning Balance at Dec. 31, 2019         $ 78,867
Beginning Balance, Shares at Dec. 31, 2019   2,651,333      
Beginning Balance at Dec. 31, 2019 $ (61,463) $ 3 $ 5,617 $ (67,083)  
Issuance of preferred stock in connection with the acquisition of Amplify Medicines, Inc.         $ 10,924
Issuance of preferred stock in connection with the acquisition of Amplify Medicines, Inc., Shares         7,863,094
Issuance of common stock in connection with the acquisition of Amplify Medicines, Inc. 2,804   2,804    
Issuance of common stock in connection with the acquisition of Amplify Medicines, Inc., Shares   426,159      
Issuance of preferred stock in connection with private placement         $ 116,188
Issuance of preferred stock in connection with private placement, Shares         85,806,214
Exercise of stock options 70   70    
Exercise of stock options, Shares   19,411      
Stock-based compensation 1,797   1,797    
Net loss and comprehensive loss $ (44,256)     (44,256)  
Ending Balance, Shares at Dec. 31, 2020 169,396,576       169,396,576
Ending Balance at Dec. 31, 2020 $ 205,979       $ 205,979
Ending Balance, Shares at Dec. 31, 2020   3,096,903      
Ending Balance at Dec. 31, 2020 (101,048) $ 3 10,288 (111,339)  
Initial public offering, net of issuance costs 131,302 $ 9 131,293    
Initial public offering, net of issuance costs, Shares   8,984,375      
Conversion of convertible preferred stock into common stock         $ (205,979)
Conversion of convertible preferred stock into common stock, Shares         (169,396,576)
Conversion of convertible preferred stock into common stock 205,979 $ 24 205,955    
Conversion of convertible preferred stock into common stock, Shares   23,678,568      
Exercise of stock options $ 582   582    
Exercise of stock options, Shares 215,188 215,188      
Stock-based compensation $ 5,177   5,177    
Net loss and comprehensive loss $ (34,115)     (34,115)  
Ending Balance, Shares at Dec. 31, 2021 0        
Ending Balance at Dec. 31, 2021 $ 0        
Ending Balance, Shares at Dec. 31, 2021   35,975,034      
Ending Balance at Dec. 31, 2021 $ 207,877 $ 36 $ 353,295 $ (145,454)